Emerging biomarkers for immune checkpoint inhibition in lung cancer
- 1 October 2018
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 52, 269-277
- https://doi.org/10.1016/j.semcancer.2018.05.006
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironmentJournal for ImmunoTherapy of Cancer, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- An Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune SystemCell, 2005
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor SignalingAnnual Review of Immunology, 1997